Health today · Cancer
refines
Among 584 US community oncology patients with CLL/SLL, half had stopped first-line ibrutinib, acalabrutinib or zanubrutinib by 24 months, most often because of adverse events.
Peer-reviewed
8 Nov 2026
Behavioural science · Adherence and persistence
refines
In 47,583 people with COPD, removing prior authorisation for LAMA preceded 0.8% more LAMA use and 1.3% less ICS/LABA use.
Peer-reviewed
8 Nov 2026
Behavioural science · Adherence and persistence
new
In English statin users aged 65 or older, stopping was linked to more hospital admissions, less so with greater frailty.
Peer-reviewed
3 Nov 2026
Health today · Heart and stroke
refines
In a US health system, 39.9% of patients with documented statin intolerance stopped all lipid-lowering therapy within 90 days.
Peer-reviewed
3 Nov 2026
Behavioural science · Adherence and persistence
confirms
Of 76,200 new antidepressant users with mood or anxiety disorders, 30.2% filled only once and 75.4% stopped within a year.
Peer-reviewed
2 Nov 2026
Behavioural science · Adherence and persistence
refines
Of 34,309 Clalit members without diabetes starting Wegovy in 2025, 67.6% had stopped by one year.
Peer-reviewed
31 Oct 2026
Behavioural science · Adherence and persistence
refines
SGLT-2 inhibitors had higher adherence and persistence than GLP-1 receptor agonists in 14,998 matched patients, most clearly with cardiovascular disease.
Peer-reviewed
31 Oct 2026
Behavioural science · Adherence and persistence
confirms
Of 9,189 adults with obesity but no diabetes starting semaglutide or tirzepatide, 18.6% had coverage for 336 days or more.
Peer-reviewed
26 Oct 2026
Behavioural science · Infection and pandemics
refines
Among 3280 virologically suppressed adults in Spain, 70.4% received every evaluable injection within ±7 days; 0.7% had suboptimal adherence.
Peer-reviewed
25 Oct 2026
Behavioural science · Adherence and persistence
refines
Among US adults starting injectable semaglutide, high-dose initiation was associated with a 25% higher early discontinuation risk and lower 1-year persistence.
Peer-reviewed
23 Oct 2026
Data, models and systems · What linked data reveals
refines
Reduced CYP2D6 activity lowered attained heart rate and raised bradycardia, but phenotype was not associated with stopping metoprolol.
Peer-reviewed
16 Oct 2026
Behavioural science · Adherence and persistence
new
Among adults starting stimulants for ADHD, median time to switching or stopping was 33.1 weeks for dexamphetamine and 15.0 weeks for methylphenidate.
Peer-reviewed
16 Oct 2026
Behavioural science · Adherence and persistence
new
Among 743,153 US adults starting semaglutide or tirzepatide for obesity in 2024, 29.9% and 35.9% respectively were still being prescribed the drug at 12 months.
Preprint · not peer-reviewed
10 Oct 2026
Behavioural science · Adherence and persistence
confirms
Among 58,754 adults aged 65 and over with type 2 diabetes, mean BMI at initiation was 33.8 for GLP-1 drugs as compared to 29.7 for SGLT2 inhibitors.
Preprint · not peer-reviewed
6 Oct 2026
Health today · Heart and stroke
new
Among 311,585 Japanese patients starting romosozumab between 2019 and 2023, 11.7% of men and 7.9% of women had a myocardial infarction or stroke in the prior 360 days, below the 8.9-17.6% among users of other osteoporosis drugs, and those with such a history discontinued more often.
Peer-reviewed
5 Oct 2026
Tomorrow's world · Medicine at a distance
refines
Across 29 studies in 8,389 stroke and transient ischaemic attack survivors, systolic blood pressure was 5.8 mmHg lower with mobile applications or wearables, though prediction intervals crossed the null.
Peer-reviewed
3 Oct 2026
Behavioural science · Adherence and persistence
new
Among 45,763 US adults with a first ischaemic stroke or TIA, 18.9% filled a P2Y12 inhibitor within 30 days, and half of clopidogrel initiators had stopped filling by 180 days.
Peer-reviewed
3 Oct 2026
Behavioural science · Adherence and persistence
refines
In propensity-matched US claims data on adults with type 2 diabetes, 12-month adherence was 60% for tirzepatide initiators against 45% for semaglutide initiators among GLP-1-naive patients, with persistence of 62% against 47%.
Peer-reviewed
3 Oct 2026
Behavioural science · Adherence and persistence
refines
Of 401,450 US women starting adjuvant endocrine therapy after breast surgery, 69.9% had a medication possession ratio of at least 80% over the first year.
Preprint · not peer-reviewed
28 Sep 2026
Behavioural science · Adherence and persistence
confirms
A retrospective cohort of 77 adults starting fostemsavir in US clinical practice found most still taking it at 12 months, and most of those already suppressed stayed suppressed.
Peer-reviewed
26 Sep 2026
Behavioural science · Adherence and persistence
confirms
Among 201,229 insured US adults with obesity and no diabetes starting a GLP-1 drug, 30.7% stayed on it for most of the following year, as did 20.3% of paediatric patients.
Peer-reviewed
20 Sep 2026